Identification of Predictive Markers of Response to the MEK1/2 Inhibitor Selumetinib (AZD6244) in K-ras–Mutated Colorectal Cancer

Mutant K-ras activity leads to the activation of the RAS/RAF/MEK/ERK pathway in approximately 44% of colorectal cancer (CRC) tumors. Accordingly, several inhibitors of the MEK pathway are under clinical evaluation in several malignancies including CRC. The aim of this study was to develop and charac...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Tentler, John J., Nallapareddy, Sujatha, Tan, Aik Choon, Spreafico, Anna, Pitts, Todd M., Morelli, M. Pia, Selby, Heather M., Kachaeva, Maria I., Flanigan, Sara A., Kulikowski, Gillian N., Leong, Stephen, Arcarol, John J., Messersmith, Wells A., Eckhardt, S. Gail
Format: Artigo
Langue:Inglês
Publié: 2010
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC3931013/
https://ncbi.nlm.nih.gov/pubmed/20923857
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-10-0376
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires